Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

NCT01301833 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

462

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: teneligliptin
DRUG: glinide
DRUG: biguanide
DRUG: alpha-glucosidase inhibitor

Sponsor

Tanabe Pharma Corporation